PECATI Trial Confirms Extended Survival for Advanced Thymic Tumors With Lenvatinib and Pembrolizumab

Final results from the phase 2 PECATI trial show that combining lenvatinib and pembrolizumab extends median overall survival to 40.2 months in patients with advanced thymic tumors. The findings offer a much-needed option for a rare cancer that has progressed after standard chemotherapy.[1][2]

The data, published in the Journal of Thoracic Oncology, confirms that the dual therapy provides sustained disease control for B3-thymoma and thymic carcinoma. These aggressive thoracic malignancies typically lack established second-line treatments once initial platinum-based regimens fail.[1][3]

Researchers tracked 43 patients across 11 hospitals in France, Italy, and Spain who had exhausted standard options. The cohort deliberately excluded individuals with lower-grade thymomas to minimize the risk of severe autoimmune reactions associated with immunotherapy.[1][5]

"The mature PECATI results provide additional evidence supporting the potential role of lenvatinib plus pembrolizumab in selected patients," investigators noted. The combination leverages both targeted anti-angiogenic properties and immune checkpoint blockade to halt tumor progression.[2][4]

Unprecedented Survival Metrics

The trial's final analysis revealed a median progression-free survival of 22.1 months, a substantial increase from the 14.9 months reported in earlier preliminary data. This metric indicates how long patients lived without their cancer worsening.[1][4]

Overall survival reached a median of 40.2 months, with 53 percent of the participants remaining alive at the three-year mark. For a patient population where 44 percent had already undergone two or more prior lines of therapy, these figures represent a significant breakthrough.[1][2]

Clinical activity was robust across the cohort, yielding an objective response rate of 25.6 percent. This included one patient who achieved a complete response, meaning all signs of the cancer disappeared entirely during the treatment period.[1][4]

Furthermore, the regimen achieved a 93 percent disease control rate, demonstrating that the vast majority of patients experienced either tumor shrinkage or stabilization. The median duration of response was not reached, suggesting the benefits were highly durable for those who responded.[1][4]

Managing Treatment Toxicity

While the efficacy data is highly encouraging, the combination therapy carries a substantial side-effect profile that requires vigilant clinical management. Grade 3 or higher treatment-related adverse events affected 44.2 percent of the trial participants.[2][3]

The intensity of these side effects led 27.9 percent of patients to discontinue at least one of the study drugs. Immune-related adverse events occurred in 39.5 percent of the cohort, highlighting the inherent risks of deploying checkpoint inhibitors in thymic malignancies.[1][2]

Severe immune complications included cases of colitis, pneumonitis, myocarditis, encephalitis, and liver toxicity. Despite these challenges, researchers reported that the safety profile remained manageable with appropriate dose modifications and corticosteroid interventions when necessary.[2][4]

Two patient deaths occurred during the study period, but investigators determined that neither was related to the experimental treatment. The protocol allowed patients to continue on a single agent if the other had to be stopped due to toxicity, provided they still derived clinical benefit.[2][5]

The Challenge of Thymic Tumors

Thymic epithelial tumors originate in the thymus, a small organ situated in the upper chest that plays a crucial role in immune system development. Because the thymus trains T-cells, cancers arising here are uniquely intertwined with autoimmune dysfunction.[1][3]

Type B3-thymoma and thymic carcinoma are the most aggressive subtypes, characterized by rapid growth and a high propensity to spread to other organs. In the PECATI cohort, 84 percent of participants had thymic carcinoma, while 16 percent had B3-thymoma.[1][4]

AI

The disease burden among participants was severe, with nearly two-thirds presenting with stage IVB cancer. More than half of the patients had metastases in at least three different sites, including 37 percent who had liver involvement.[1][5]

Historically, treating these advanced stages relied almost entirely on platinum-based chemotherapy, which eventually loses its effectiveness. Once the cancer becomes refractory to platinum drugs, oncologists have had to rely on off-label regimens with limited evidence of long-term success.[1][3]

A Synergistic Mechanism

The PECATI trial's success stems from the synergistic action of its two component drugs, which attack the tumor through entirely different biological pathways. Lenvatinib is a multi-targeted tyrosine kinase inhibitor that primarily disrupts the blood vessels feeding the cancer.[1][5]

By starving the tumor of its blood supply, lenvatinib alters the microenvironment, making the cancer cells more vulnerable to immune attack. Pembrolizumab, an immune checkpoint inhibitor, then blocks the PD-1 pathway, effectively removing the brakes from the patient's own T-cells.[1][5]

This dual approach appears to overcome the resistance mechanisms that typically thwart single-agent therapies in thymic carcinoma. Dr. Jordi Remon, the trial's principal investigator from Gustave Roussy in France, emphasized that the combination surpasses the activity of either agent used alone.[1][5]

Participants received a daily oral dose of 20 milligrams of lenvatinib alongside a 200-milligram intravenous infusion of pembrolizumab every three weeks. Treatment continued until disease progression, unacceptable toxicity, or the completion of 35 cycles over two years.[1][4]

Shaping Future Guidelines

The mature data from the PECATI trial provides a compelling case for updating clinical guidelines to include the lenvatinib and pembrolizumab combination. Currently, the National Comprehensive Cancer Network lists single-agent therapies as preferred options for second-line treatment.[1][2]

However, the 88.4 percent progression-free survival rate at five months significantly outperforms historical benchmarks for pembrolizumab monotherapy. This establishes a new efficacy standard for future trials aiming to improve outcomes in platinum-refractory thymic malignancies.[5]

Because thymic tumors are exceptionally rare, conducting large, randomized phase 3 trials is logistically challenging. Consequently, robust phase 2 data like the PECATI results often serve as the primary basis for regulatory approvals and shifts in standard clinical practice.[1][3]

Moving forward, researchers stress the need for prospective studies to determine the optimal sequencing of these therapies. Identifying specific biomarkers could also help oncologists predict which patients are most likely to benefit while avoiding severe immune-related toxicities.[4]

Ultimately, the extended survival demonstrated in this trial offers tangible hope to patients facing one of thoracic oncology's most difficult diagnoses. The findings confirm that targeted immunotherapy combinations can fundamentally alter the trajectory of advanced thymic cancer.[1][2]

Collaborative European Research

The successful execution of the PECATI trial highlights the vital importance of cross-border collaboration in studying rare orphan diseases. By pooling resources across 11 specialized centers in France, Italy, and Spain, investigators were able to recruit a statistically meaningful cohort.[5]

Investigator-initiated studies like this one often fill critical knowledge gaps that pharmaceutical companies might overlook due to small patient populations. The oncology community has widely praised the effort to promote academic trials in rare thoracic conditions.[1][5]

The trial's multidisciplinary approach also underscores how managing advanced thymic tumors requires coordinated expertise. Pulmonologists, thoracic surgeons, and medical oncologists must work together to balance the aggressive treatment of the malignancy against the heightened risk of autoimmune complications.[1][3]